MacroGenics, Inc.

( )
MGNX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -5.01%54.820.0%$1460.45m
GILDGilead Sciences, Inc. -0.48%72.831.0%$1281.27m
AMGNAmgen, Inc. 0.10%222.631.3%$638.12m
NVAXNovavax, Inc. -0.56%47.90102.0%$605.25m
REGNRegeneron Pharmaceuticals, Inc. -2.07%533.952.5%$604.25m
VRTXVertex Pharmaceuticals, Inc. 0.14%266.861.9%$517.02m
BIIBBiogen, Inc. 2.08%302.021.6%$421.60m
ILMNIllumina, Inc. -0.25%353.533.5%$353.87m
SRNESorrento Therapeutics, Inc. 1.90%5.371.8%$312.89m
SGENSeattle Genetics, Inc. 3.14%156.506.1%$250.68m
ALXNAlexion Pharmaceuticals, Inc. 0.97%103.802.0%$226.24m
AAgilent Technologies, Inc. 1.37%86.141.6%$196.15m
CODXCo-Diagnostics, Inc. -1.28%17.800.0%$183.56m
MGNXMacroGenics, Inc. -1.44%23.306.2%$175.70m
BMRNBioMarin Pharmaceutical, Inc. 6.39%103.744.3%$172.63m

Company Profile

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.